found Documents: 861

Announcements & Press Releases, Regulatory Notice | 20 Mar 2018

Grant of Share Options under Share Option Scheme

1 item

London: Tuesday, March 20, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 19, 2018, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 19 Mar 2018

Director's Share Dealing

1 item

London: Monday, March 19, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company (“ADSs”,

Grant of Share Options under Share Option Scheme

Director's Share Dealing

Publication of Form 20-F for the Year Ended December 31, 2017

Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China

Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer

Chi-Med to Announce 2017 Final Results

Total Voting Rights

Blocklisting Six Monthly Return

Chi-Med Initiates Fruquintinib U.S. Clinical Trials

TR-1: Notification of major interest in shares

TR-1: Notification of major interest in shares

Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer

Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market

Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market

Chi-Med Announces Proposed Offering of ADSs (RNS)

Chi-Med Announces Proposed Offering of ADSs

TR-1: Notification of major interest in shares

Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification

Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer

Chi-Med Appoints Professor Tony Mok to Board of Directors

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

Total Voting Rights

Director's Share Dealing

Chi‑Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL‑689 in Lymphoma Patients in China

Director's Share Dealing

Directors' Share Dealing

Directors' Share Dealing

Director’s Share Dealing

Directors' Share Dealing

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

Total Voting Rights

Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma

Blocklisting Six Monthly Return

Chi-Med to Announce 2017 Half-Year Financial Results

Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China

Director’s Share Dealing

Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer

Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO

Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting

Total Voting Rights

Results of Annual General Meeting

Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

Total Voting Rights

Vesting of awards under the Long Term Incentive Plan

Grant of Share Options under Share Option Scheme

2016 Annual Report and Notice of Annual General Meeting